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Abstract 
The liver exhibits intrinsic immune tolerogenic properties that contribute to a unique propensity 
toward spontaneous acceptance when transplanted, both in animal models and in humans. 
Thus, in contrast to what happens after transplantation of other solid organs, several years 
following liver transplantation a significant subset of patients are capable of maintaining normal 
allograft function with histological integrity in the absence of immunosuppressive drug treatment. 
Significant efforts have been put into identifying sensitive and specific biomarkers of tolerance in 
order to stratify liver transplant recipients according to their need for immunosuppressive 
medication and their likelihood of being able to completely discontinue it. These biomarkers are 
currently being validated in prospective clinical trials of immunosuppression withdrawal both in 
Europe and in the United States. These studies have the potential to transform the clinical 
management of liver transplant recipients by mitigating, at least in part, the burden of lifelong 
immunosuppression. 
Abstract word count: 147. 
  
  
1. Introduction 
Liver transplantation (LT) is currently the most successful treatment for end-stage liver failure. 
Remarkable improvements in short-term allograft and transplant recipient survival have been 
achieved in the last three decades, due in part to advances in surgical techniques and 
perioperative care, but also to the introduction of powerful immunosuppressive drug treatments 
(ISDT) such as calcineurin inhibitors. However, the lifelong use of conventional ISDT, which is 
required to avoid the risk of rejection and graft loss in the majority of patients, is associated with 
severe side-effects and increased recipient morbidity and mortality. Amongst complications 
negatively impacted by chronic ISDT, de novo malignancies, infections, chronic renal failure, as 
well as cardiovascular and metabolic diseases, are the most clinically relevant and altogether 
constitute the main causes of late LT patient increased mortality [1, 2]. 
It is now well recognized that the liver exhibits numerous intrinsic immunoregulatory properties 
that contribute to a unique propensity toward spontaneous acceptance in the context of 
transplantation and to a far lower risk of graft loss secondary to rejection episodes, as compared 
with other transplanted organs [3-8]. For example, successful LT can be done without human 
leukocyte antigen (HLA) matching, across a positive crossmatch, with lower 
immunosuppressive requirements than other organs, and liver allografts can recover from 
advanced acute and chronic rejection episodes [4, 9-11]. Moreover, recent data indicate that, 
using simple clinical, histological and demographic criteria, it is possible to identify a small 
proportion of liver transplant recipients with approximately 40% chance of being able to 
successfully discontinue ISDT, depending mainly on recipient age and timing after LT [3, 12-14]. 
These patients, who can accept the implanted allograft without ISDT for a prolonged period of 
time, maybe indefinitely, are considered to have developed a state of spontaneous operational 
tolerance (SOT). Although LT recipients meeting these criteria represent a small proportion of 
the overall transplant population, they have become the focus of intense study. The concrete 
  
clinical opportunity provided by LT patients has fueled the need to identify accurate biomarkers 
of immune tolerance in order to maximize the benefits that can be derived from ISDT 
withdrawal. Here we review recent advances in this field.   
2. Clinical characteristics of liver transplant recipients achieving spontaneous 
operational tolerance 
In the setting of LT and on the basis of early retrospective and/or single-center studies, a 20% 
prevalence of SOT was proposed [3, 15-24]. However, this estimation did not take into account 
the heterogeneity of the inclusion and exclusion criteria employed in the different studies and 
the fact that, at least in adult recipients, the likelihood of successful ISDT discontinuation is 
greatly dependent on recipient age and on the time elicited since transplantation [12-14, 25-27]. 
In the study by Benitez et al., for instance, the effect of time since transplantation was striking, 
with 13%, 38% and 79% of patients achieving successful ISDT withdrawal depending on 
whether at inclusion in the study they were <6 years, between 6 and 11 years, and >11 years 
post-transplant respectively [12]. Taking together the accumulated clinical experience from the 
early studies and the data derived from the more recent prospective clinical trials, the current 
agreement is that successful ISDT withdrawal is observed in approximately 40% of recipients 
when they are selected on the basis of the following criteria: a) >3 years (preferably >6 years) 
post-transplant; b) no history of autoimmune liver disease; c) no recent episodes of rejection; 4) 
normal or minimally altered liver histology. These are precisely the patient enrolment criteria 
being employed in the 2 large multi-centre ISDT withdrawal trials currently underway in the 
United States and Europe (OPTIMAL trial: NCT02533180 and LIFT trial: NCT02498977 
respectively). The results of major published and unpublished biomarker studies in spontaneous 
operational tolerance following liver transplantation are summarized in Table 1 [12-16, 18, 20-
39]. 
 
  
3. Biomarkers of spontaneous operational tolerance in liver transplantation 
3.1. Clinical utility of biomarkers of immune tolerance and technical considerations 
Because of a significant risk of graft rejection after ISDT withdrawal, there is still a need for 
prospective identification of individuals who have become operationally tolerant (TOL) to their 
LT. In this context, biomarker research was developed in order to identify SOT LT recipients 
prior to ISDT weaning and thus, to reduce radically the risk of rejection. Identification of a 
reproducible and reliable tolerance «signature» is one of the goals of this research because 
these biomarkers would substantially benefit the LT population, in modifying the equipoise in 
favor of ISDT discontinuation in a subgroup of selected patients.  
Schematically, the clinical utility of biomarkers of tolerance can be considered in 3 situations:  
1. As a prediction tool, in guiding patient selection for ISDT withdrawal or tolerance 
induction protocols;  
2. As a stratification/clinical decision making tool, in indicating the optimal timing or strategy 
by which ISDT withdrawal or tolerance induction are most likely to succeed for a patient;  
3. As a monitoring tool, in serving as an indicator of success or failure of an attempt to 
establish tolerance.  
The ever-expanding “-omics” disciplines have provided major opportunities to the identification 
of biomarkers relevant to transplantation (so called “Transplantomics” [40-42]) and, in particular, 
to the field of LT. The microarray technology, for instance, has been widely employed to 
evaluate the whole transcriptome of blood and/or liver tissue samples from solid-organ 
transplant patients. The reproducibility of some of these studies is still an open question, 
however, given that many solid-organ transplant studies employing high-throughput molecular 
technologies are small and most likely underpowered. Furthermore, biological interpretations 
  
have been hampered by the fact that there is still a limited understanding on how many 
biomarkers relate to conventional clinical and immunological outcomes [43]. 
3.2. Flow cytometric immune cell subset analyses 
Early approaches to biomarker discovery in SOT LT recipients involved the analyses of 
peripheral blood mononuclear cells (PBMC) by flow cytometry. In a Japanese cohort of 12 
pediatric SOT LT recipients, Li et al. reported an increased frequency of CD4+CD25+ regulatory 
T cells (Tregs), B cells, and a higher ratio of Vδ1/Vδ2 gamma-delta (γδ) T cells [32]. The latter 
observation was confirmed in a subsequent study conducted in adult LT recipients [44]. 
However, Puig-Pey et al. demonstrated that alterations in the γδ T cell compartment were not 
restricted to TOL LT recipients [45]. In fact, most immunosuppressed kidney and LT recipients 
also displayed an enlarged peripheral blood γδ T cell pool, mainly resulting from an expansion 
of Vδ1 T cell subset. The increased proportion of Vδ1 T cells was associated with viral 
infections (cytomegalovirus, hepatitis C infection [HCV]), raising doubts as to the specificity of 
this marker for tolerance [38, 45]. Finally, Bohne et al. conducted a prospective open-label non-
controlled ISDT withdrawal trial in which adult HCV-infected stable LT recipients were 
progressively weaned off immunosuppression [38]. A favorable inclusion biological profile was 
required, that is with high blood Vδ1/Vδ2 T cell ratio and/or elevated SLAMF7/KLRF1 transcript 
levels. The authors demonstrated that blood Vδ1/Vδ2 T cell ratio was useful in the screening of 
LT recipients for ISDT withdrawal, with an interesting discriminative capacity (82% sensitivity, 
53% specificity, 67% positive predictive value, 73% negative predictive value) [38]. They also 
found that HCV-positive TOL LT recipients were exhibiting an expansion of immune-exhausted 
HCV-specific CD8+ T lymphocytes [38]. This population of T cells are defined as exhausted 
because they display a decreased proliferative capacity (through the expression of inhibitory 
receptors such as PD1 and CTLA4) which can be reversed after inhibitory receptor blockade 
[38]. 
  
Like the above-mentioned Japanese group, several other groups also identified increases in 
peripheral Tregs in SOT recipients [21, 32, 46]. Pons et al. carried out a prospective study to 
investigate the dynamic profile of the Tregs population in LT recipients during ISDT withdrawal. 
An increase in the frequency of CD4+CD25+ T cells and in the relative mRNA FoxP3 
expression during the ISDT weaning process was observed only in the TOL recipients, and not 
in those patients who eventually developed rejection [21]. 
Plasmacytoid dendritic cells (DCs) represent another cell population with regulatory functions. 
Tolerogenic plasmacytoid DCs have a low capacity for T cell stimulatory functions and a high 
capacity for inducing tolerogenicity, mainly through downregulation of MHC class II and 
costimulatory molecules, upregulation of inhibitory factors and secretion of effector molecules 
and regulatory cytokines (e.g. nitric oxide, IL-10) [47]. In the context of SOT LT recipients, 
plasmacytoid DCs were observed at higher frequencies in some [48], but not all analyses [44].  
Finally, at the graft level, immune cell subset analyses yielded interesting results too. The 
aforementioned Japanese group expanded their findings in PBMC from pediatric LT recipients 
to show the γδ T cell «signature» to extend to the graft itself [39]. In separate work, they also 
described significant accumulations of Tregs in allograft biopsy samples [49]. 
3.3 Anti-HLA antibodies 
The pathogenic role of preexisting or de novo anti-HLA donor-specific antibodies (DSAs) is well 
established after kidney transplantation. In this setting, DSAs represent a risk factor for the 
development of acute and chronic rejection, as well as graft loss and patient death [50, 51]. In 
contrast to kidney transplantation, the liver allograft has been traditionally considered resistant 
to the effects of DSAs. Recently, increasing evidence suggests that DSAs are associated with 
acute and chronic liver allograft rejection and many other post-transplant complications (e.g. 
fibrosis progression, ductopenia, biliary complications), which may have detrimental 
  
consequences on allograft and patient outcomes [52-55]. However, these data are mainly 
issued from single-center retrospective studies and remain contentious. 
The potential relevance of DSA monitoring during or after ISDT withdrawal was first proposed 
by Girnita et al. in 2010 [56]. Employing an enzyme-linked immunosorbent assay, the authors 
observed no DSAs in successfully weaned LT recipients, as compared to recipients under 
minimal or normal ISDT. These results were not confirmed by Feng et al. in a prospective multi-
centre drug withdrawal trial in pediatric recipients [13]. In this study, neither HLA mismatch nor 
presence of DSAs (assessed by single antigen bead assays) were associated with the outcome 
of ISDT withdrawal [13]. The absence of association between DSAs (detected by enzyme-linked 
immunoassay, complement-dependent cytotoxicity or flow cytometry) and ISDT withdrawal 
outcome was also pointed out in the study by Benitez et al. [12, 57]. On the other hand, in a 
Japanese cross-sectional study of 81 pediatric living-donor LT recipients, anti-HLA-DRB1 DSAs 
(detected by single antigen bead assay), as well as anti-angiotensin II type 1 receptor 
antibodies, were found to be associated with the presence of long-term progressive graft fibrosis  
[57]. 
In conclusion, DSAs remain a topic of debate in the field of LT. DSAs are in fact a reflect of 
donor sentitization and could therefore represent a potential barrier for the establishment of 
tolerance. However, in the setting of LT, the uncertainty as to what constitutes the pathogenic 
determinants of anti-HLA antibodies renders this field difficult to interpret in the context of the 
prediction of SOT.  
3.4. Transcriptional profiling 
3.4.1 PBMC gene expression 
An alternative approach to cytometric analyses was initiated by Martínez-Llordella et al., using 
microarray technology gene-expression profiling of PBMC from SOT LT recipients [44]. In a 
  
retrospective, cross-sectional study, 16 SOT LT recipients were compared to 16 non-tolerant 
(Non-TOL) recipients, and 462 positively and 166 negatively regulated genes were identified. 
The tolerance-associated molecular «signature» revealed by this study encoded predominantly 
for natural killer (NK) and γδ T cell receptor-related transcripts and thus, was corroborating 
preceding cell subset analyses. The following year, the same group published a more robust 
analysis of a larger cohort of patients and incorporated both training and validation sets, as well 
as the necessary cross-validation checkpoint procedures, with the aim of validating the 
predictive capacity of their microarray method [34]. A novel modeling approach, based on the 
misclassified penalized posterior algorithm, yielded a «signature» comprised of only a small 
number of genes, containing 2, 6 and 7 genes, respectively and altogether comprising 12 
different genes. These «signatures» were shown to be capable of providing high diagnostic 
accuracy in the identification of tolerance, not only in the group of recipients from whom they 
were derived but also of an independent validation cohort of 23 subjects. 
However, despite a very good diagnostic performance of these blood-based transcriptional 
biomarker test and the confirmation of the overrepresentation of transcripts preferentially 
expressed by NK cells in TOL patients, the reproducibility of the test in a multi-centre 
prospective trial was found to be insufficient, rendering blood-based PBMC molecular 
«signature» test unreliable to predict the outcome of ISDT withdrawal [36]. This clearly 
represents an area where there is room for additional research. As an example, in a 
retrospective cross-sectional study, Li et al. amalgamated multi-centric living and deceased 
donor and pediatric, as well as adult data, gene expression data and identified a 13-gene 
peripheral blood tolerance «signature» [58]. This «signature» was highly associated with NK 
cells and proved to have a high predictive accuracy (100% sensitivity, 83% specificity). 
γδ T cells, NK cells and tolerance: γδ T cell are “non-conventional” T cells that participate in 
both innate and adaptive immunity as cytolytic effector cells, but that are also involved in 
  
immunoregulatory responses. The Vδ1 T cell subtype, which is usually not the predominant 
subpopulation in the peripheral blood of healthy adults, preferentially populates epithelial tissues 
such as the intestine, where it has been implicated in local immunoregulatory processes, most 
likely through the killing of either effector T cells, antigen-presenting cells or stressed epithelial 
cells [44, 59]. Typically, Vδ1 T cell subtype express the activating NK receptors NKG2D and 
CD160, which contribute to promote their cytolytic effector function [44, 59]. Moreover, genes 
encoding for γδ T cell and NK receptors are known for their potential to regulate mitosis and cell 
proliferation. This could corroborate the fact that the above-mentioned Vδ1/Vδ2 T cell ratio is an 
interesting marker of tolerance, when increased in relation to an expansion of the Vδ1 T cell 
population. 
Differences and similarities between kidney and liver transplant tolerance profiles: Most kidney 
studies have coincided in the identification of a B cell related transcriptional «signature» in 
blood, associated with an expansion of B cells with a transitional and/or an IL-10 producing 
phenotype [60-64]. The kidney and liver blood-derived transcriptional profiles have been directly 
compared by Lozano et al., which revealed that there were no similarities neither at the 
transcriptional nor at the flow cytometry level [65]. 
3.4.2 Liver tissue gene expression 
Mechanistic interpretations of the above-mentioned studies were limited by their retrospective 
design, which could not exclude the confounding effect of pharmacological immunosuppression 
(i.e. ISDT-free TOL patients were compared with Non-TOL recipients under ISDT), and the lack 
of simultaneous molecular analyses of allograft tissue. In 2012, the group led by Sánchez-
Fueyo published data from a prospective, multi-centre trial of ISDT withdrawal in LT recipients 
[36]. Of 75 LT recipients completing the trial, 42 (56%) underwent rejection, while 33 (44%) 
were successfully weaned off ISDT and proved to reach a state of SOT. Both flow cytometric 
and gene-expression analyses of PBMC confirmed the overrepresentation of NK cells and NK-
  
related gene sets in TOL recipients. However, the PBMC molecular «signature» lacked 
reproducibility across the participating centres and could not reliably predict the outcome of 
ISDT withdrawal. The most accurate and reproducible predictor of ISDT withdrawal outcome 
proved to be the liver tissue-derived transcriptional profile obtained at baseline. Interestingly, the 
intragraft expression profile showed no overlap with genes identified from PBMC. In fact, liver 
biopsy microarrays validated by real-time polymerase chain reaction (RT-PCR) showed that, 
among the 10 genes showing transcriptional differences of greatest magnitude in relation to 
tolerance (TRFC, PEBP1, MIF, CDHR2, SOCS1, IFNG, HAMP, SLC5A12, DAB2, HMOX1), 
there was an overrepresentation of those involved in iron metabolism. These included 
transferrin receptor 1 (TRFC), hepcidin (HAMP), and macrophage inhibitory factor (MIF). A 
combination of 5 of the 10 biopsy-derived genes, when measured prior to ISDT weaning, was 
extremely accurate at discriminating those LT recipients who could successfully withdraw ISDT 
from those who could not. This predictive «signature» contained the following 5 genes: SOCS1, 
TFRC, PEBP1, MIF, CHDR2, and predicted the outcome of ISDT withdrawal with a sensitivity of 
89% and a specificity of 86% (area under the curve 85%, positive predictive value 80%, 
negative predictive value 92%). This was consistent with the finding that TOL and Non-TOL 
recipients differed in hepcidin and ferritin serum levels, as well as in hepatocyte iron deposition 
(higher in LT recipients successfully weaned from ISDT).  
Iron metabolism and tolerance: The interplay between iron homeostasis and tolerance is not 
fully elucidated. It appears to be clear that inflammation, through a mechanism dependant on 
interleukin 6 (IL-6), induce a rapid increase of hepcidin, which reduces iron export from 
enterocytes, hepatocytes and macrophages [66-68]. This results in iron accumulation within 
macrophages and decreased circulating iron levels, which represents an effective defense 
strategy against extracellular microorganisms that need access to iron to exert their pathogenic 
effect [66, 68]. In addition to various effects on innate immune responses and inflammation, iron 
  
is also required for the function and differenciation of adaptive immune cells such as T cells. 
Iron deficiency impairs T cell proliferation in vitro [66, 69]. In their recent description utilizing a 
well characterized mouse model of immunomediated hepatitis, Bonaccorsi-Riani et al. showed 
that iron-hepcidin axis was important in the regulation of intrahepatic lymphocyte activation and 
function [66].  
The assessment of clinical utility and safety of the above-mentioned graft-derived 5-genes 
«signature» predictive of SOT is the primary objective of a prospective, randomized, multi-
centre and international, biomarker-based trial of ISDT withdrawal, currently recruiting patients 
in Europe (Liver Immunosuppression Free Trial [LIFT]: NCT02498977 and EudraCT number 
2014-004557-14) and supported by the UK National Institute of Health Research, as well as the 
BIODrIM (BIOmarker-Driven Personalized Immunosuppression) EU consortium (Figure 1). 
Study participants are randomized 1:1 to either non-biomarker-based ISDT weaning (Arm A) or 
biomarker-based ISDT weaning (Arm B). In Arm A, ISDT is withdrawn regardless of the result of 
biomarker test. In Arm B, only those found to be “biomarker-positive” (Arm B+, i.e. positive for 
the validated liver tissue-derived gene expression «signature» indicative of tolerance) are 
offered ISDT withdrawal; participants with a negative biomarker test result (Arm B-) will remain 
on their baseline maintenance ISDT. The trial includes the prospective and sequential collection 
of numerous biological specimens to conduct ancillary mechanistic studies. 
Two additional ongoing multi-centre clinical trials in the United States, both supported by the 
Immune Tolerance Network and also by the National Institute of Allergy and Infectious Diseases 
and the National Institute of Diabetes and Digestive and Kidney for the former, iWITH 
(Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients, 
NCT01638559) and OPTIMAL (Evaluation of Donor Specific Immune Senescence and 
Exhaustion as Biomarkers of Tolerance Post Liver Transplantation, NCT02533180), will provide 
further opportunities for biomarker crossvalidation. 
  
3.5. Potential confounding effects of pharmacological immunosuppression on tolerance 
biomarker profiles 
The capacity of routinely employed immunosuppressants to influence tolerance-related cellular 
and transcriptional biomarkers has recently been highlighted by Rebollo-Mesa et al. in the 
setting of kidney transplantation [70]. While this has not been explored in such detail in LT, it 
could have influenced the results of some of the reported studies outlined above, which 
employed a case-control cross-sectional design. A clear example of this risk is the observation 
by Bohne et al. that TOL recipients exhibit a higher number of circulating CD4+CD25+Foxp3+ 
regulatory T cells (Tregs) than non-TOL patients but only at the end of the drug withdrawal 
protocol (once tolerant patients no longer receive calcineurin inhibitors) and not before weaning 
is initiated [36]. The risk of immunosuppressants modifying biomarker profiles derived from 
prospective ISDT withdrawal trials is significantly lower than in case-control studies but cannot 
be completely excluded, particularly in what regards blood-derived biomarkers. For this reason, 
it is imperative to specifically explore the potential influence of these medications, as well as 
other treatments. To date this has only been reported for the liver tissue transcriptional 
«signature» described by Bohne et al., which was found to predict the outcome of ISDT 
withdrawal independently from the type of immunosuppression administered at the initiation of 
the trial.   
4. Conclusions 
Long-term outcomes in LT are hampered by the burden of lifelong ISDT. ISDT withdrawal or 
minimization could be a logical solution to this problem. This goal seems to be more feasible in 
the context of LT than in other transplantation settings, as the liver allograft exhibits a relatively 
privileged immune tolerance status. In order to identify patients suitable for a safe withdrawal or 
minimization of these medications, substantial effort has been devoted to identify biomarkers 
with high sensitivity and specificity. Based on these pioneering studies, the first biomarker-led, 
  
prospective ISDT withdrawal trials are underway and promise further progress in tolerance 
biomarker research. To date most studies have provided descriptive immunophenotyping 
information derived from multi-parameter flow cytometry and gene expression approaches, and 
there has been very little emphasis on elucidating the characteristics of donor-specific functional 
responses. A thorough mechanistic understanding of the TOL phenotype will require 
incorporation of such strategies into the current biomarker pipelines.  
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Year of 
publication 
Authors Total 
number of 
LT patients 
analysed 
Number of 
TOL  
LT patients 
Number of 
non-TOL 
LT patients 
Number 
of STA LT 
patients 
Biomarkers 
1998 [16] Devlin et al. 18 5 12 0  Donor-derived microchimerism (-) 
1998 [28] Wong T et al. 37 6 24 0  Liver tissue immunostaining studies 
2001 [30] Takatsuki et al. 23 23 0 0  Mixed lymphocyte reaction 
 Intra-graft cytokine profiles 
2003 [31] Mazariegos et al. 40 6 34* 0  Plasmacytoid DC/monocytoid DC ratio (+) 
2003 [22] Pons et al. 9 3 6 0  Endothelial cell chimerism (-) 
2008 [21] Pons et al. 12 5 7 0  Peripheral blood CD4+CD25
high
 T cells (+) 
 PBMC gene expression (+) 
2004 [32] Li et al. 31 12 0 19  PBMC subsets: CD4+CD25
high
 T cells (+), B cells 
(+), Vδ1/Vδ2 gamma-delta T cell ratio (+) 
2008 [34] Martinez-Llordella et al. 80 28 33 19  Peripheral blood gene expression 
2011 [35] Castellaneta et al. 78 26 28* 24  HLA-G expression on circulating monocytoid DC 
(+) 
2012 [13] Feng et al. 20 12 8 0  Anti-HLA antibodies 
 Liver biopsy C4d score 
2013 [12] 
2012 [36] 
2016 [37] 
Benitez et al. 
Bohne et al. 
Taubert et al. 
102 41 61 0  Anti-HLA antibodies 
 PBMC and liver tissue gene expression 
 Blood cell immunophenotyping 
 Iron status parameters 
 Liver tissue immunofluorescence 
2013 [14] de la Garza et al. 24 15 9 0  Stimulation index of circulating lymphocytes 
following phytohemagglutinin stimulation 
2013 [39] Zhao et al. 34 9 17 0  Intragraft Vδ1/Vδ2 gamma-delta T cell ratio (+) 
 CDR3 sequencing of the δ chain of Vδ1 cells 
2014 [38] Bohne et al. 34 17 15 0  Blood Vδ1/Vδ2 gamma-delta T cell ratio (+) 
 Blood SLAMF7/KLRF4 gene expression (+) 
 Liver tissue gene expression 
 Anti-HCV Elispot T cell responses 
 Exhaustion markers in circulating HCV-specific 
CD8+ T cells  
Unpublished 
[27] 
Feng et al. 88 33 55 0  Anti-HLA antibody subclasses; auto-antibodies 
 Liver biopsy C4d score 
 Liver tissue multi-parameter immunofluorescence 
 Liver tissue gene expression 
  
Table 1. Biomarker studies in spontaneous operational tolerance following liver transplantation. 
*Patients with unknown status of tolerance (e.g. patients undergoing prospective ISDT weaning, patients with follow-up shorter than 
1 year post-ISDT withdrawal) are also included in this category. 
(+), positive association with a successful ISDT withdrawal  
(-), negative or no association with a successful ISDT withdrawal 
CDR3, complementarity-determining region 3; HCV, hepatitis C virus; HLA, human leukocyte antigen; ISDT, immunosuppressive 
drug treatment; LT, liver transplant; N/A, not applicable; Non-TOL, non-tolerant; PBMC, peripheral blood mononuclear cell; STA, 
stable LT recipients receiving maintenance immunosuppressive drugs; TOL, tolerant. 
 
 
 
 
 
  
  
Figure 1. Liver Immunosuppression Free Trial (LIFT) flow diagram (NCT02498977). 
 
After a clinical eligibility screening and a confirmation histological eligibility screening through a baseline liver biopsy (see www.clinicaltrial.gov for 
detailed inclusion and exclusion criteria), consenting study participants are randomized 1:1 to either non-biomarker-based immunosuppressive 
drug treatment (ISDT) weaning (Arm A) or biomarker-based ISDT weaning (Arm B). 
The biomarker test used in this trial is a validated liver graft-derived 5-genes signature which is highly predictive of spontaneous operational 
tolerance, before ISDT withdrawal. In Arm A, ISDT is withdrawn regardless of the result of biomarker test. In Arm B, only those found to be 
“biomarker-positive” (Arm B+) are offered ISDT withdrawal; participants with a negative biomarker test result (Arm B-) will remain on their baseline 
maintenance ISDT.  
 
ISDT, immunosuppressive drug treatment; PIs, principal investigators. 
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